MedTrace Logo

An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B

NCT03901755 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 151

Last updated 2025-09-29

No results posted yet for this study

Summary

Alprolix (rFIXFc) is a recombinant extended half-life coagulation factor product. The purpose of this non-interventional study is to describe the real-world usage and effectiveness of Alprolix in the on-demand and prophylactic treatment of haemophilia B.

Conditions

  • Hemophilia B

Interventions

DRUG

Alprolix

Extended half-life factor IX product

Sponsors & Collaborators

  • Swedish Orphan Biovitrum

    lead INDUSTRY

Principal Investigators

  • Elena Santagostino, MD · Swedish Orphan Biovitrum

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-12
Primary Completion
2024-03-12
Completion
2024-03-12

Countries

  • Czechia
  • Greece
  • Ireland
  • Italy
  • Norway
  • Saudi Arabia
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03901755 on ClinicalTrials.gov